IFIH1 and myositis disease: Another retrospective study (24) analyzed the profile of myositis autoantibodies (MAs) in the sera of 788 patients with suspected MSA and confirmed Sars-CoV-2 infection and/or vaccination from 11 Spanish hospitals in 2022, revealing an anti-MDA5+ prevalence of 11.66%.